ACE2-RBD inhibition was median 21.7% in those with breakthrough infection (n = 3, mean 16.1%) following the first vaccine dose (median 309 days from infection to sampling) and median 46.8% in those with infection following the second vaccine dose (n = 4) (median 85 days from infection to sampling). The gene discussed is ACE2; the disease is infection.